|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL49 |
Gene summary for MRPL49 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL49 | Gene ID | 740 |
| Gene name | mitochondrial ribosomal protein L49 | |
| Gene Alias | C11orf4 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | A0A024R578 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 740 | MRPL49 | LZE4T | Human | Esophagus | ESCC | 5.94e-08 | 1.92e-01 | 0.0811 |
| 740 | MRPL49 | LZE7T | Human | Esophagus | ESCC | 4.03e-07 | 2.72e-01 | 0.0667 |
| 740 | MRPL49 | LZE8T | Human | Esophagus | ESCC | 1.20e-06 | 1.55e-01 | 0.067 |
| 740 | MRPL49 | LZE20T | Human | Esophagus | ESCC | 2.60e-03 | 1.62e-01 | 0.0662 |
| 740 | MRPL49 | LZE24T | Human | Esophagus | ESCC | 8.32e-20 | 5.50e-01 | 0.0596 |
| 740 | MRPL49 | LZE6T | Human | Esophagus | ESCC | 7.23e-04 | 2.03e-01 | 0.0845 |
| 740 | MRPL49 | P1T-E | Human | Esophagus | ESCC | 5.81e-03 | 1.99e-01 | 0.0875 |
| 740 | MRPL49 | P2T-E | Human | Esophagus | ESCC | 2.96e-26 | 5.04e-01 | 0.1177 |
| 740 | MRPL49 | P4T-E | Human | Esophagus | ESCC | 5.68e-32 | 8.76e-01 | 0.1323 |
| 740 | MRPL49 | P5T-E | Human | Esophagus | ESCC | 3.37e-16 | 3.83e-01 | 0.1327 |
| 740 | MRPL49 | P8T-E | Human | Esophagus | ESCC | 4.52e-20 | 4.09e-01 | 0.0889 |
| 740 | MRPL49 | P9T-E | Human | Esophagus | ESCC | 1.31e-18 | 2.66e-01 | 0.1131 |
| 740 | MRPL49 | P10T-E | Human | Esophagus | ESCC | 3.90e-24 | 4.48e-01 | 0.116 |
| 740 | MRPL49 | P11T-E | Human | Esophagus | ESCC | 5.33e-13 | 6.27e-01 | 0.1426 |
| 740 | MRPL49 | P12T-E | Human | Esophagus | ESCC | 4.88e-31 | 7.81e-01 | 0.1122 |
| 740 | MRPL49 | P15T-E | Human | Esophagus | ESCC | 1.38e-23 | 6.66e-01 | 0.1149 |
| 740 | MRPL49 | P16T-E | Human | Esophagus | ESCC | 1.78e-38 | 8.21e-01 | 0.1153 |
| 740 | MRPL49 | P17T-E | Human | Esophagus | ESCC | 1.02e-07 | 2.94e-01 | 0.1278 |
| 740 | MRPL49 | P19T-E | Human | Esophagus | ESCC | 1.64e-10 | 8.62e-01 | 0.1662 |
| 740 | MRPL49 | P20T-E | Human | Esophagus | ESCC | 2.19e-20 | 5.30e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL49 | SNV | Missense_Mutation | c.34G>C | p.Gly12Arg | p.G12R | Q13405 | protein_coding | tolerated(0.79) | benign(0) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| MRPL49 | SNV | Missense_Mutation | novel | c.85N>G | p.Thr29Ala | p.T29A | Q13405 | protein_coding | tolerated(0.25) | benign(0) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL49 | SNV | Missense_Mutation | rs539335985 | c.286G>A | p.Val96Ile | p.V96I | Q13405 | protein_coding | tolerated(0.05) | possibly_damaging(0.583) | TCGA-D1-A16J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| MRPL49 | SNV | Missense_Mutation | c.4N>C | p.Ala2Pro | p.A2P | Q13405 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-DD-A1EA-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| MRPL49 | SNV | Missense_Mutation | novel | c.430N>G | p.Thr144Ala | p.T144A | Q13405 | protein_coding | tolerated(0.23) | benign(0.114) | TCGA-95-7567-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
| MRPL49 | SNV | Missense_Mutation | novel | c.367N>C | p.Asp123His | p.D123H | Q13405 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-33-4587-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | etoposide | PD |
| MRPL49 | SNV | Missense_Mutation | rs748704915 | c.332G>A | p.Arg111Gln | p.R111Q | Q13405 | protein_coding | tolerated(0.05) | benign(0.356) | TCGA-BR-7707-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL49 | SNV | Missense_Mutation | rs539335985 | c.286G>A | p.Val96Ile | p.V96I | Q13405 | protein_coding | tolerated(0.05) | possibly_damaging(0.583) | TCGA-HJ-7597-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR |
| MRPL49 | deletion | Frame_Shift_Del | novel | c.314delN | p.Gln106ArgfsTer2 | p.Q106Rfs*2 | Q13405 | protein_coding | TCGA-BR-6458-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |